Biolinq, a San Diego, CA-based healthcare expertise firm offering precision multi-analyte biosensors, raised $100M in Collection C funding.
The spherical was led by Alpha Wave Ventures, with participation from current buyers RiverVest Enterprise Companions, AXA IM Alts, LifeSci Enterprise Companions, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Options Capital.
The corporate intends to make use of the funds to assist its transition from growth stage to business readiness following US pivotal trial completion and regulatory submission.
Led by CEO Wealthy Yang, Biolinq is a healthcare expertise firm offering precision multi-analyte wearable sensors to enhance metabolic well being. Its platform is designed to tell and encourage to assist more healthy residing.
Biolinq’s glucose sensor patch positioned on the higher forearm includes a color-changing indicator gentle, offering customers with real-time suggestions to remain knowledgeable about glucose excursions. it’s designed for ease of use and reliability leveraging a biosensing platform that permits future multi-analyte sensing capabilities.
FinSMEs
23/04/2025
